A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

NCT05785819 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Veralox Therapeutics Business Decision.

Conditions

Thrombocytopenia, Immune
Heparin Induced Thrombocytopenia

Interventions

DRUG: VLX-1005
DRUG: Placebo

Sponsor

Veralox Therapeutics